GH Research PLC
NASDAQ:GHRSBiotechnology
-$0.04 today
- Market cap
- $1.25B
- Beta
- 1.31
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.91
Volume 0.46M
Average 0.23M
GHRS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
GH Research PLCNASDAQ: GHRS
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at $242.65M at the end of Q1 FY2026, down 0.9% from a year earlier and down 1.5% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.
Context
- Cash & equivalents amounted to 88.2% of total assets at the end of Q1 FY2026, up 11.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -0.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 246.25M USD
- Year-over-year change
- +144.3%
- 4-year CAGR
- -2.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 246.25M | +144.3% |
| FY2024 | 2024-12-31 | 100.79M | +28.5% |
| FY2023 | 2023-12-31 | 78.42M | -52.7% |
| FY2022 | 2022-12-31 | 165.96M | -40.0% |
| FY2021 | 2021-12-31 | 276.78M | — |
Cash & Equivalents vs competitors
How GHRS compares with its peers on the latest reported figures
- GHRS's Mar 2026 cash & equivalents of $242.65M is the 4th highest of the 9 companies compared; the peer median is $239.59M.
- Its year-over-year change of -0.9% is the lowest of 9, against a peer median of +53.8%.
- Cash & equivalents amounts to 88.2% of total assets for GHRS, versus a peer median of 45.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $24.65B | +161575.2% | +31.6% | 25.9% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M | +2154.3% | +126.9% | 81.5% |
| Mar 2026 | $263.76M | +64.1% | +54.0% | 95.5% | |
| Mar 2026 | $242.65M | -0.9% | +14.1% | 88.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $241.15M | +1108.2% | +22.0% | 22.4% |
| Jun 2026 | $238.03M | +43.6% | +3.9% | 64.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $147.07M | +15.9% | -8.8% | 95.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $78.06M | +35.5% | +19.1% | 15.7% |
| Mar 2026 | $55.71M | +11.1% | +19.1% | 13.3% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding GHRS) | $239.59M | +53.8% | +20.5% | 45.1% | |
Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 276.78M | 165.96M | 78.42M | 100.79M | 246.25M |
| Short-term Investments | 0 | 0 | 83.14M | 48.53M | 34.46M |
| Net Receivables | 48K | 90K | 178K | 1.73M | 1.3M |
| Inventory | 3.01M | (90K) | 0 | 0 | 0 |
| Other Current Assets | 10K | 47K | 119K | 0 | 0 |
| Total Current Assets | 279.84M | 168.54M | 164.09M | 154.23M | 285.98M |
| Property, Plant & Equipment (Net) | 82K | 97K | 1.07M | 748K | 620K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 85.72M | 61.14M | 33.3M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 1.63M |
| Total Non-current Assets | 82K | 85.82M | 62.21M | 34.05M | 2.25M |
| Total Assets | 279.92M | 254.36M | 226.3M | 188.27M | 288.23M |
| Account Payables | 883K | 1.87M | 3.49M | 3.74M | 3.77M |
| Short-term Debt | 0 | 0 | 343K | 255K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 168K | 312K | 6.36M | 8.7M | 407K |
| Total Current Liabilities | 2.75M | 4.55M | 6.7M | 8.95M | 8.38M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 1.87M | 631K | 369K | 147K |
| Total Liabilities | 2.75M | 4.55M | 7.33M | 9.32M | 8.53M |
| Common Stock | 1.3M | 1.3M | 1.3M | 1.3M | 1.55M |
| Retained Earnings | (10.04M) | (32.49M) | (67.94M) | (106.45M) | (154.43M) |
| Accumulated OCI | (5.54M) | (10.44M) | (5.86M) | (7.37M) | 1.52M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 277.18M | 249.82M | 218.97M | 178.95M | 279.7M |
| Total Debt | 0 | 0 | 974K | 624K | 512K |
| Net Debt | (276.78M) | (165.96M) | (77.45M) | (100.17M) | (245.74M) |
GH Research PLC
NASDAQ:GHRS
Intrinsic Alpha fair value
Locked
Current Price
$18.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.